Oncology commands roughly 40% of the national drug spend. Retina is close behind. “If you follow the drug spend, you’ll find that the distributors are really building an ecosystem around it,” says Jeanne Proia, managing director at Cross Keys Capital and president of its healthcare services group.
In this conversation with McGuireWoods partner and host Geoff Cockrell, Jeanne unpacks the market. Unlike traditional PE deals, she says, these transactions leave physicians holding their own equity inside a long-term MSO relationship, trading the second bite at the apple for cash upfront and taking the risk off.
As she explains: “They’re able to bring a lot more synergies just because they’re getting to be bigger and bigger, and they can use that money to support all the synergies, whether it’s clinical trials, recruiting or RCM.”